IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v10y2019i1d10.1038_s41467-019-11413-4.html
   My bibliography  Save this article

Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML

Author

Listed:
  • Thomas Oellerich

    (Goethe University of Frankfurt
    German Cancer Consortium/German Cancer Research Center
    Frankfurt Cancer Institute, Goethe University Frankfurt)

  • Constanze Schneider

    (Goethe University of Frankfurt
    Frankfurt Cancer Institute, Goethe University Frankfurt
    University of Frankfurt)

  • Dominique Thomas

    (Goethe University of Frankfurt)

  • Kirsten M. Knecht

    (Yale University)

  • Olga Buzovetsky

    (Yale University)

  • Lars Kaderali

    (University Medicine Greifswald)

  • Christoph Schliemann

    (University Hospital Münster)

  • Hanibal Bohnenberger

    (University Medical Center)

  • Linus Angenendt

    (University Hospital Münster)

  • Wolfgang Hartmann

    (University Hospital Münster)

  • Eva Wardelmann

    (University Hospital Münster)

  • Tamara Rothenburger

    (University of Frankfurt)

  • Sebastian Mohr

    (Goethe University of Frankfurt)

  • Sebastian Scheich

    (Goethe University of Frankfurt)

  • Federico Comoglio

    (Cambridge University)

  • Anne Wilke

    (Goethe University of Frankfurt)

  • Philipp Ströbel

    (University Medical Center)

  • Hubert Serve

    (Goethe University of Frankfurt
    German Cancer Consortium/German Cancer Research Center
    Frankfurt Cancer Institute, Goethe University Frankfurt)

  • Martin Michaelis

    (University of Kent)

  • Nerea Ferreirós

    (Goethe University of Frankfurt)

  • Gerd Geisslinger

    (Goethe University of Frankfurt
    Project group Translational Medicine and Pharmacology (TMP))

  • Yong Xiong

    (Yale University)

  • Oliver T. Keppler

    (University of Frankfurt
    LMU München)

  • Jindrich Cinatl

    (University of Frankfurt)

Abstract

Hypomethylating agents decitabine and azacytidine are regarded as interchangeable in the treatment of acute myeloid leukemia (AML). However, their mechanisms of action remain incompletely understood, and predictive biomarkers for HMA efficacy are lacking. Here, we show that the bioactive metabolite decitabine triphosphate, but not azacytidine triphosphate, functions as activator and substrate of the triphosphohydrolase SAMHD1 and is subject to SAMHD1-mediated inactivation. Retrospective immunohistochemical analysis of bone marrow specimens from AML patients at diagnosis revealed that SAMHD1 expression in leukemic cells inversely correlates with clinical response to decitabine, but not to azacytidine. SAMHD1 ablation increases the antileukemic activity of decitabine in AML cell lines, primary leukemic blasts, and xenograft models. AML cells acquire resistance to decitabine partly by SAMHD1 up-regulation. Together, our data suggest that SAMHD1 is a biomarker for the stratified use of hypomethylating agents in AML patients and a potential target for the treatment of decitabine-resistant leukemia.

Suggested Citation

  • Thomas Oellerich & Constanze Schneider & Dominique Thomas & Kirsten M. Knecht & Olga Buzovetsky & Lars Kaderali & Christoph Schliemann & Hanibal Bohnenberger & Linus Angenendt & Wolfgang Hartmann & Ev, 2019. "Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML," Nature Communications, Nature, vol. 10(1), pages 1-14, December.
    • Handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-11413-4
    DOI: 10.1038/s41467-019-11413-4
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-019-11413-4
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/s41467-019-11413-4?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-11413-4. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.